Ethyl 4-hydroxy-6-methylnicotinate | 1374433-79-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: Ethyl 4-hydroxy-6-methylnicotinate
• 英文别名: ethyl 6-methyl-4-oxo-1H-pyridine-3-carboxylate
• CAS: 1374433-79-0；33946-27-9
• 化学式: C₉H₁₁NO₃
• 分子量: 181.191
• InChiKey: DITACZWZKUMRFW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Ethyl 4-hydroxy-6-methylnicotinate 在 苄基三乙基氯化铵 、 三氯氧磷 作用下， 以 乙腈 为溶剂， 反应 1.0h， 以44%的产率得到1,2-二氢-2-氧代-4-氯-6-甲基吡啶-3-羧酸乙酯
  参考文献：
  名称：

  Discovery of the investigational drug TAK-441, a pyrrolo[3,2-c]pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: Modification of the core skeleton for improved solubility

  摘要：

  We recently reported the discovery of the novel pyrrolo[3,2-c] quinoline-4-one derivative 1 as a potent inhibitor of Hedgehog (Hh) pathway signaling. However, the PK evaluation of 1 at high dosage (100 mg/kg) revealed the C-max value 3.63 mu g/mL, likely due to poor solubility of this compound. Efforts to improve solubility by reducing the aromatic ring count of the core system led to N-methylpyrrolo[3,2-c]pyridine derivative 11. Further optimization of the 3-alkoxy group led to compound 11d with acceptable solubility and potent Hh inhibitory activity. Compound 11d suppressed transcription factor Gli1 mRNA expression in tumor-associated stromal tissue and inhibited tumor growth (treatment/control ratio, 3%) in a mouse medulloblastoma allograft model owing to the improved PK profile based on increased solubility. Compound 11d (TAK-441) is currently in clinical trials for the treatment of advanced solid tumors. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.07.034

文献信息

• Pyridone Derivatives
  申请人：DAIICHI SANKYO COMPANY, LIMITED

  公开号：US20130281428A1

  公开（公告）日：2013-10-24

  Novel compounds or salts thereof, or crystals thereof, which inhibit Axl and are useful for treating diseases caused by Axl hyperfunction, diseases associated with Axl hyperfunction and/or diseases accompanied by Axl hyperfunction are provided. Pyridone derivatives represented by the formula (1) having various substituents or salts thereof, or crystals thereof (where R 1 , R 2 , R 3 , R 5 , R 6 , A, W, X and n in the formula (1) are as defined in the specification, respectively) are provided.

  提供了抑制Axl并用于治疗由Axl高功能引起的疾病、与Axl高功能相关的疾病和/或伴随Axl高功能的疾病的新型化合物或其盐，或其晶体。提供了由式（1）所代表的吡啶酮衍生物，具有各种取代基或其盐，或其晶体（其中式（1）中的R1、R2、R3、R5、R6、A、W、X和n分别如规范中定义）。
• Surface protection film
  申请人：NITTO DENKO CORPORATION

  公开号：EP2657277A1

  公开（公告）日：2013-10-30

  The invention provides a surface protection film 1 comprising a top coat layer 14 on a first face 12A of a substrate 12, and a pressure-sensitive adhesive layer 20 on a second face 12B. The top coat layer 14 comprises a wax as a slip agent, and a polyester resin as a binder. Here, the wax is an ester of a higher fatty acid and a higher alcohol.

  本发明提供了一种表面保护膜 1，它包括位于基材 12 第一面 12A 上的表层 14 和位于第二面 12B 上的压敏胶层 20。表层 14 包括作为滑爽剂的蜡和作为粘合剂的聚酯树脂。在这里，蜡是一种高级脂肪酸和高级醇的酯。
• MITTELBACH, MARTIN;JUNEK, HANS
  作者：MITTELBACH, MARTIN、JUNEK, HANS

  DOI：——

  日期：——
• PYRIDONE DERIVATIVE
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP2810937B1

  公开（公告）日：2016-11-30
• SURFACE PROTECTION FILM
  申请人：NITTO DENKO CORPORATION

  公开号：US20130280527A1

  公开（公告）日：2013-10-24

  The invention provides a surface protection film including a top coat layer on a first face of a substrate, and a pressure-sensitive adhesive layer on a second face. The top coat layer includes a wax as a slip agent, and a polyester resin as a binder. Here, the wax is an ester of a higher fatty acid and a higher alcohol.